Eurocine Vaccines AB
Climate Impact & Sustainability Data (2016, 2021-07 to 2023-06)
Reporting Period: 2016
Environmental Metrics
Climate Goals & Targets
Long-term Goals:
- Market launch of Immunose™ FLU (2022/2023).
Medium-term Goals:
- Secure a partnership agreement (by 2018).
Short-term Goals:
- Initiate and complete clinical phase I/II study (by Summer 2017).
Environmental Challenges
- Weak market confidence due to past failures to meet targets and repeated equity offerings.
- Concentrated market with high barriers to entry.
- Main patent expiring in 2017.
- Need for additional funding if partnership is not secured.
Mitigation Strategies
- Shifting strategy from whole virus to split antigen to meet industry demands.
- Securing capital for clinical phase I/II study.
- Seeking partnerships to secure funding and market access.
- Exploring new indications for Endocine™ technology.
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2021-07 to 2023-06
Environmental Metrics
Climate Goals & Targets
Long-term Goals:
- Design, plan and prepare a clinical study, combined phase I/IIA - starting in 2026
Medium-term Goals:
- Continued process development for toxicological and first clinical study (2025)
- Consultative meeting with regulatory authority (2025)
- Continued preclinical studies (2025)
- Intensified business development (2025)
Short-term Goals:
- Preclinical pilot study in guinea pigs (2024)
- Preclinical study in HSV-2-infected guinea pigs (2024)
- Decision on which technology to use - protein or mRNA-based vaccine (2024)
- Initial process development (2024)
- Evaluation of the potential for a prophylactic HSV-2 vaccine (2024)
- Continued business development to strengthen relationships with potential licensees (2024)
Environmental Challenges
- Insufficient working capital to continue operations from February 2024.
- Risk of not raising any capital in the offering.
- Risk of unsatisfactory results in required studies, potentially preventing product launch.
- Risk of not obtaining necessary approvals and registrations from authorities.
- Risk of increased competition from multinational companies.
- Risk of failure to enter into successful collaboration and licensing agreements.
- Risk of patent applications not being approved or granted patents not providing long-term protection.
- High and unpredictable development costs.
- Risk of loss of key personnel.
Mitigation Strategies
- Conducting a rights issue to raise capital.
- Exploring alternative financing options such as additional capital raising, grants, or reducing the pace of operations.
- Committing to new development activity costs only to the extent that sufficient funding has been provided through the rights issue.